José Willegaignon

Summary

Publications

  1. doi request reprint Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy
    José Willegaignon
    Nuclear Medicine Center, Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
    Radiat Prot Dosimetry 149:138-46. 2012
  2. doi request reprint Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure
    José Willegaignon
    Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
    Clin Nucl Med 36:440-5. 2011
  3. ncbi request reprint Is it necessary to reduce the radioiodine dose in patients with thyroid cancer and renal failure?
    José Willegaignon
    Departamento de Radiologia, Universidade de Sao Paulo, SP, Brazil
    Arq Bras Endocrinol Metabol 54:413-8. 2010
  4. doi request reprint Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
    José Willegaignon de Amorim de Carvalho
    Nuclear Medicine Center, Department of Radiology, Clinical Hospital, School of Medicine, University of Sao Paulo, Brazil
    Nucl Med Commun 30:533-41. 2009
  5. ncbi request reprint Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models
    J Willegaignon
    Nuclear Medicine Center, Instituto de Radiologia, Faculdade de Medicina, Universidade de Sao Paulo, Brazil
    Health Phys 93:678-88. 2007
  6. ncbi request reprint A new proposal for monitoring patients in nuclear medicine
    J Willegaignon
    Radiological Protection Service, Instituto de Pesquisas Energéticas e Nucleares, Av Prof Lineu Prestes, 2242, Cidade Universitaria, CEP 05508 000, Sao Paulo, Brazil
    Health Phys 91:624-9. 2006
  7. ncbi request reprint Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy
    J Willegaignon
    Radiological Protection Service, Instituto de Pesquisas Energéticas e Nucleares, Cidade Universitaria, Sao Paulo, Brazil
    Health Phys 91:123-7. 2006
  8. ncbi request reprint 131I effective half-life (Teff) for patients with thyroid cancer
    J Willegaignon
    Radiological Protection Service, Instituto de Pesquisas Energéticas e Nucleares, Cidade Universitaria, Sao Paulo, Brazil
    Health Phys 91:119-22. 2006
  9. doi request reprint Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning
    José Willegaignon
    Department of Radiology, Nuclear Medicine Service and Laboratory of Medical Investigation LIM 43 and Cancer Institute of São Paulo State ICESP, Clinical Hospital, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
    Clin Nucl Med 38:231-6. 2013
  10. ncbi request reprint [Correlation between thyroid volume determined either by ultrasound or by scintigraphy and its implications in dosimetric radioiodine calculations in Graves disease treatment]
    Lucas de Oliveira Vieira
    Serviço de Medicina Nuclear, Instituto de Radiologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brasil
    Arq Bras Endocrinol Metabol 55:696-700. 2011

Collaborators

Detail Information

Publications14

  1. doi request reprint Comparison of different dosimetric methods for red marrow absorbed dose calculation in thyroid cancer therapy
    José Willegaignon
    Nuclear Medicine Center, Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
    Radiat Prot Dosimetry 149:138-46. 2012
    ..The use of OLINDA/EXM in clinical routine could possibly diminish data collection, thus giving rise to a simultaneous reduction in time and clinical costs, besides avoiding any kind of discomfort on the part of the patients involved...
  2. doi request reprint Outpatient radioiodine therapy for thyroid cancer: a safe nuclear medicine procedure
    José Willegaignon
    Department of Radiology, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
    Clin Nucl Med 36:440-5. 2011
    ..4 GBq. The following parameters were thus defined: (a) whole-body radiation doses to caregivers, (b) the production of contaminated solid waste, and (c) radiation potential and surface contamination within patients' living quarters...
  3. ncbi request reprint Is it necessary to reduce the radioiodine dose in patients with thyroid cancer and renal failure?
    José Willegaignon
    Departamento de Radiologia, Universidade de Sao Paulo, SP, Brazil
    Arq Bras Endocrinol Metabol 54:413-8. 2010
    ..It also permits the safe and potential delivery of higher doses of radiation to tumors and undesirable tissues, with a minimum of malignant effects on healthy tissues...
  4. doi request reprint Could the treatment of differentiated thyroid carcinoma with 3.7 and 5.55 GBq of (131I)NaI, on an outpatient basis, be safe?
    José Willegaignon de Amorim de Carvalho
    Nuclear Medicine Center, Department of Radiology, Clinical Hospital, School of Medicine, University of Sao Paulo, Brazil
    Nucl Med Commun 30:533-41. 2009
    ....
  5. ncbi request reprint Correction factors for more accurate estimates of exposure rates near radioactive patients: experimental, point, and line source models
    J Willegaignon
    Nuclear Medicine Center, Instituto de Radiologia, Faculdade de Medicina, Universidade de Sao Paulo, Brazil
    Health Phys 93:678-88. 2007
    ..The results given here provide more accuracy in evaluation of exposure rates and consequently absorbed doses near radioactive patients and allow for more effective radiological protection procedures during patient management...
  6. ncbi request reprint A new proposal for monitoring patients in nuclear medicine
    J Willegaignon
    Radiological Protection Service, Instituto de Pesquisas Energéticas e Nucleares, Av Prof Lineu Prestes, 2242, Cidade Universitaria, CEP 05508 000, Sao Paulo, Brazil
    Health Phys 91:624-9. 2006
    ..These findings suggest a new methodology for patients' measurement in nuclear medicine and could be useful for personal monitoring in cases of radiological emergencies involving 131I ingestion...
  7. ncbi request reprint Evaluation of the potential absorbed doses from patients based on whole-body 131I clearance in thyroid cancer therapy
    J Willegaignon
    Radiological Protection Service, Instituto de Pesquisas Energéticas e Nucleares, Cidade Universitaria, Sao Paulo, Brazil
    Health Phys 91:123-7. 2006
    ..0 +/- 0.7 to 8.4 +/- 1.1 mSv at 1 m and 1.2 +/- 0.4 to 3.2 +/- 0.4 mSv at 2 m. The data reported here are important to radioprotection policy and to add to and improve on the guidelines reported in U.S. NRC Regulatory Guide 8.39...
  8. ncbi request reprint 131I effective half-life (Teff) for patients with thyroid cancer
    J Willegaignon
    Radiological Protection Service, Instituto de Pesquisas Energéticas e Nucleares, Cidade Universitaria, Sao Paulo, Brazil
    Health Phys 91:119-22. 2006
    ..41 +/- 0.02 h; this information may be used in guidelines on the management of patients in thyroid cancer therapy and for general radioprotection practice...
  9. doi request reprint Radioiodine therapy for Graves disease: thyroid absorbed dose of 300 Gy-tuning the target for therapy planning
    José Willegaignon
    Department of Radiology, Nuclear Medicine Service and Laboratory of Medical Investigation LIM 43 and Cancer Institute of São Paulo State ICESP, Clinical Hospital, School of Medicine, University of Sao Paulo, Sao Paulo, Brazil
    Clin Nucl Med 38:231-6. 2013
    ....
  10. ncbi request reprint [Correlation between thyroid volume determined either by ultrasound or by scintigraphy and its implications in dosimetric radioiodine calculations in Graves disease treatment]
    Lucas de Oliveira Vieira
    Serviço de Medicina Nuclear, Instituto de Radiologia, Hospital das Clinicas, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brasil
    Arq Bras Endocrinol Metabol 55:696-700. 2011
    ..In radiodosimetric calculations to determine radioiodine dosage it is possible to use thyroid volume estimatives based on ultrasound or scintigraphy...
  11. ncbi request reprint [Radioiodine therapy of differentiated thyroid cancer: radiologic impact of out-patient treatment with 100 to 150 mCi Iodine-131 activities]
    Marcelo Tatit Sapienza
    Serviço de Medicina Nuclear, Departamento de Radiologia, Faculdade de Medicina, Universidade de São Paulo FMUSP, Sao Paulo, SP, Brasil
    Arq Bras Endocrinol Metabol 53:318-25. 2009
    ..To evaluate exposure and dosimetry to family members and environment due to outpatient radioiodine therapy of differentiated thyroid carcinoma...
  12. doi request reprint Determining thyroid (131)I effective half-life for the treatment planning of Graves' disease
    José Willegaignon
    School of Medicine, University of São Paulo, Sao Paulo, Brazil
    Med Phys 40:022502. 2013
    ..With the aim of optimizing this process, this study presents a practical, propitious, and accurate method of determining T(eff) for dosimetric purposes...
  13. ncbi request reprint The feasibility of sentinel lymph node detection in patients with previous transaxillary implant breast augmentation: preliminary results
    Alexandre Mendonça Munhoz
    Division of Plastic Surgery, University of Sao Paulo School of Medicine, Rua Oscar Freire 1702 ap 78, Sao Paulo, SP, 05409 011, Brazil
    Aesthetic Plast Surg 29:163-8. 2005
    ..Sentinel lymph node detection (SLND) is a well-established technique in breast cancer. To date, no information is available regarding the feasibility of SLND for patients with previous transaxillary implants...
  14. ncbi request reprint The influence of subfascial transaxillary breast augmentation in axillary lymphatic drainage patterns and sentinel lymph node detection
    Alexandre Mendonça Munhoz
    Division of Plastic Surgery, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
    Ann Plast Surg 58:141-9. 2007
    ..To date, no information is available regarding the feasibility of SLN identification in patients with previous transaxillary breast augmentation (TBA)...